Equity Overview
Price & Market Data
Price: $23.20
Daily Change: -$0.27 / 1.16%
Range: $22.56 - $24.00
Market Cap: $1,480,778,880
Volume: 906,424
Performance Metrics
1 Week: 9.07%
1 Month: -10.38%
3 Months: -31.54%
6 Months: -42.96%
1 Year: -41.24%
YTD: -45.09%
Company Details
Employees: 112
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company's lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.